The tool for early detection of dementia

Neurosalience® is a tool for early detection of dementia from structural MRI and CT data capable of processing even low-resolution MRI data and CT scans.

brain

Current Problems

In the world due to population ageing it is predicted that the number of patients with dementia will rise to 75 million by 2030.

In UK average cost per patient is over 32 000 pounds a year. Current diagnostic pipeline allows only to start treatment and lifestyle changes once the symptoms have occurred.

mental health

75 million patients by 2030

elderly person

Average cost = £32K per patient

phonendoscope

Existing screening methods:

-Lack sensitivity

-Are not automated enough

-Detect existing symptoms

dementia

The first tool for assessing low-resolution MRI data and extending to CT

At Neurosalience we develop a tool for early detection of dementia from structural MRI scans. The tool is the first in the world to be capable of assessing risk of dementia even on low resolution MRI data and be extendable to be used on CT data.

Early detection of the risk of dementia allows to reduce long-term patient-related care costs and improve the quality of life of the people as there are scientifically proven lifestyle changes enabling to decelerate the course of disease.

At Neurosalience we develop a tool for early detection of dementia from structural MRI scans.

We use interpretable machine learning algorithms to assess brain ageing.

view our technology
product

News & Achievements

Apr 13, 2023
ec logo

CEO of Neurosalience was awarded €75,000 by European Innovation Council (EISMEA)

about the award
Dec 15, 2021
hf logo

Neurosalience was one of the two winners at the Health Founders Demo Day

about the event
view all news

Partner with us!

We are open to collaboration and partnership with hospitals, MedTech and pharma companies. Contact us to arrange a demo of our product!

Our partners